Shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) have received an average broker rating score of 1.00 (Strong Buy) from the four brokers that cover the stock, Zacks Investment Research reports. Four investment analysts have rated the stock with a strong buy rating.

Brokerages have set a 12 month consensus target price of $34.33 for the company, according to Zacks. Zacks has also assigned Deciphera Pharmaceuticals an industry rank of 167 out of 265 based on the ratings given to its competitors.

DCPH has been the topic of a number of recent analyst reports. Instinet initiated coverage on Deciphera Pharmaceuticals in a research report on Monday, October 23rd. They set a “buy” rating and a $57.00 price target on the stock. Nomura initiated coverage on Deciphera Pharmaceuticals in a research report on Monday, October 23rd. They set a “buy” rating and a $57.00 price target on the stock. JMP Securities initiated coverage on Deciphera Pharmaceuticals in a research report on Monday, October 23rd. They set an “outperform” rating and a $38.00 price target on the stock. J P Morgan Chase & Co initiated coverage on Deciphera Pharmaceuticals in a research report on Monday, October 23rd. They set an “overweight” rating and a $30.00 price target on the stock. Finally, Piper Jaffray Companies initiated coverage on Deciphera Pharmaceuticals in a research report on Monday, October 23rd. They set an “overweight” rating and a $35.00 price target on the stock.

Shares of Deciphera Pharmaceuticals (DCPH) traded down $0.07 during midday trading on Friday, reaching $19.01. The company’s stock had a trading volume of 118,563 shares, compared to its average volume of 184,382.

In other Deciphera Pharmaceuticals news, major shareholder New Leaf Venture Management Ii purchased 375,000 shares of the stock in a transaction on Monday, October 2nd. The shares were purchased at an average price of $17.00 per share, with a total value of $6,375,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Institutional investors have recently bought and sold shares of the company. Kornitzer Capital Management Inc. KS acquired a new position in shares of Deciphera Pharmaceuticals in the third quarter valued at approximately $2,172,000. Emerald Mutual Fund Advisers Trust acquired a new position in shares of Deciphera Pharmaceuticals in the third quarter valued at approximately $5,548,000. Finally, Emerald Advisers Inc. PA acquired a new position in shares of Deciphera Pharmaceuticals in the third quarter valued at approximately $6,661,000.

COPYRIGHT VIOLATION WARNING: “Zacks: Brokerages Set $34.33 Price Target for Deciphera Pharmaceuticals, Inc. (DCPH)” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another site, it was copied illegally and reposted in violation of U.S. & international copyright laws. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/11/03/zacks-brokerages-set-34-33-price-target-for-deciphera-pharmaceuticals-inc-dcph.html.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is developing drugs to improve the lives of cancer patients. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib. Its proprietary kinase switch control inhibitor platform, inhibit the activation of kinases.

Get a free copy of the Zacks research report on Deciphera Pharmaceuticals (DCPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.